Search

everythinglearnresearchcommunity

for

Search:↓

ENERGI-F701 solution was found to be more effective and safer than Regaine® 2% minoxidil solution in treating female pattern hair loss, with increased hair density and less side effects.

Enobosarm significantly increased muscle mass and improved physical function in elderly men and postmenopausal women without serious side effects.

DHL-HisZnNa may help reduce hair loss from chemotherapy, but more research is needed.

KX-826 is safe and effectively increases hair count in men with hair loss.

The drug combination was safe and showed promise in treating advanced tumors.

The drug IPI-926 is safe at 160 mg daily and may help treat certain tumors, especially basal cell carcinoma.

Tempol is safe and may prevent hair loss from brain radiotherapy.

Injections of special skin cells showed potential in treating hair loss, with some participants experiencing increased hair density.

The new chemotherapy combination for advanced lung cancer showed a 35.7% response rate but caused significant side effects.

Future research on ectodysplasin should explore its role in diseases, stem cells, and evolution, and continue developing treatments for genetic disorders like hypohidrotic ectodermal dysplasia.

Topical minoxidil does not change the activity of hair follicle enzymes that metabolize it.

The reconstructed skin model from hair follicles functions like human skin in processing chemicals and can be used to test ingredient safety.

Patients with metastatic breast cancer treated with epirubicin and docetaxel had a good response and maintained their quality of life.

Wearing a frozen glove during chemotherapy can reduce nail and skin problems but may not be comfortable for everyone.

Most patients experienced mild to moderate skin problems during a trial for a desmoid tumor treatment.

The combination treatment showed a higher response rate but no significant survival benefits.

Reconstructed skin models are useful for studying how skin processes certain chemicals.

Boron neutron capture therapy for head and neck cancer can cause side effects like mouth sores and skin irritation, which vary depending on where the treatment is aimed.

Androgenetic alopecia trials in the U.S. lack racial and ethnic diversity, limiting their applicability.

Targeted cancer therapies have a significant but lower risk of causing hair loss compared to chemotherapy.

A man developed skin lesions as a side effect of a gamma secretase inhibitor used for treating a tumor.

Hair loss is a common, often overlooked side effect of hormone treatments for breast and prostate cancer.

Docetaxel is safe and works well for older people with cancer, with manageable side effects.

BAY 43-9006 helps control kidney cancer growth but doesn't significantly increase overall survival.

Over 30 potential cancer prevention treatments are being tested, with some showing promise in early research.

Liposomes show promise in cancer treatment by delivering drugs with less toxicity and improved effectiveness.

Docetaxel is effective against various cancers but mainly causes neutropenia.

The PDGF/PDGFR pathway is a potential drug target with mixed success in treating various diseases, including some cancers and fibrosis.

Epirubicin is as effective as doxorubicin for cancer treatment with less heart damage, but doesn't work on doxorubicin-resistant cancers.

A man with vitiligo and alopecia saw quick skin and hair improvement with ruxolitinib, but skin color gains were lost after stopping treatment.